摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl (10S,11R,12R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate | 57-22-7

中文名称
——
中文别名
——
英文名称
methyl (10S,11R,12R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
英文别名
——
methyl (10S,11R,12R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate化学式
CAS
57-22-7
化学式
C46H56N4O10
mdl
——
分子量
825.0
InChiKey
OGWKCGZFUXNPDA-DLBZMDDPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    211-216 ºC
  • 比旋光度:
    D25 +17°; D25 +26.2° (ethylene chloride)
  • 沸点:
    761.92°C (rough estimate)
  • 密度:
    1.1539 (rough estimate)
  • 溶解度:
    溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。
  • 物理描述:
    Vincristine appears as a white crystalline solid. Melting point 218°C. Used as an antineoplastic.
  • 颜色/状态:
    Blades from methanol
  • 稳定性/保质期:
    STERILE SOLN IN EITHER H2O OR PHYSIOLOGICAL SALINE STORED IN REFRIGERATOR FOR UP TO 2 WK WITHOUT SIGNIFICANT LOSS OF POTENCY
  • 旋光度:
    Specific optical rotation: +17 deg at 25 °C/D; +26.2 deg at 25 °C/D (ethylene chloride); max absorption (ethanol): 220, 255, 296 nm (log molar absorptivity = 4.65, 4.21, 4.18)
  • 分解:
    When heated to decomposition it emits toxic fumes of oxides of nitrogen.
  • 解离常数:
    pKa: 5.0, 7.4 in 33% dimethylformamide

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    60
  • 可旋转键数:
    10
  • 环数:
    9.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    171
  • 氢给体数:
    3
  • 氢受体数:
    12

ADMET

代谢
静脉注射[放射性同位素标记的]长春新碱后,72小时内,69%的放射性物质在粪便中回收,12%在尿液中回收。大约一半是以代谢物的形式存在,其紫外光谱表明长春新碱二聚体保持完整。胆瘘患者显示出完整的药物(46.5%)和代谢物(53.5%)的广泛胆汁排泄。观察结果表明,胆汁-粪便途径在排泄中占主导地位。
After iv administration of ... (3)H vincristine, 69% of radioactivity was recovered in feces and 12% in urine over 72 hr period. Approx half ... was in form of metabolites, whose UV spectrum suggested that vincristine dimer was intact. Patients with biliary fistula showed extensive biliary excretion of intact drug (46.5%) & of metabolites (53.5%). Observations suggest that biliary-fecal route ... predominate in excretion ... .
来源:Hazardous Substances Data Bank (HSDB)
代谢
长春新碱的代谢命运尚未明确确定;该药物似乎被广泛代谢,可能是在肝脏中,但代谢的程度不清楚,因为药物在体内也显然会分解。
The metabolic fate of vincristine has not been clearly determined; the drug appears to be extensively metabolized, probably in the liver, but the extent of metabolism is not clear since the drug also apparently undergoes decomposition in vivo.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
硫酸长春新碱与伊曲康唑(已知是代谢途径的抑制剂)同时给药据报道会导致神经肌肉副作用更早出现和/或增加严重程度(见不良反应)。这种相互作用被认为与抑制长春新碱的代谢有关。
Concurrent administration of vincristine sulfate with itraconazole (a known inhibitor of the metabolic pathway) has been reported to cause an earlier onset and/or an increased severity of neuromuscular side effects (see Adverse Reactions). This interaction is presumed to be related to inhibition of the metabolism of vincristine.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
口服或静脉注射苯妥英钠与包括硫酸长春新碱在内的抗肿瘤化疗方案同时给药,据报道会降低抗惊厥药物的血液水平并增加癫痫发作活动。剂量调整应基于连续的血药浓度监测。硫酸长春新碱对此相互作用的贡献尚不确定。这种相互作用可能是由苯妥英钠吸收减少以及其代谢和排泄速率增加所导致。
The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. Dosage adjustment should be based on serial blood level monitoring. The contribution of vincristine sulfate to this interaction is not certain. The interaction may result from reduced absorption of phenytoin and an increase in the rate of its metabolism and elimination.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
牛脑神经节苷脂对长春新碱神经毒性的影响在10天鸡胚背根神经节细胞的离体培养中进行了研究。药物的作用通过计算具有神经突起的细胞数量或单个具有神经突起的细胞中神经突起的总长度来量化。长春新碱(1至1000 pg/mL)的给药抑制了细胞的神经突起生长,而神经节苷脂(10至1000 ug/mL)以浓度依赖性的方式对抗这种抑制作用。电子显微镜揭示了长春新碱诱导神经突起中的微管碎片化和纵向错位,并显示了神经节苷脂对这种损害作用的防护。结果表明,外源性给予神经节苷脂可以减轻长春新碱在体外的神经毒性。
The effects of bovine brain gangliosides on the neurotoxicity of vincristine were investigated in dissociated cultures of dorsal root ganglion cells from 10 day chick embryos. The effects of the drugs were quantified as the numbers of neurite bearing cells or total neurite length in individual neurite bearing cells. The administration of vincristine (1 to 1000 pg/mL) inhibited neurite outgrowth from the cells, whereas gangliosides (10 to 1000 ug/mL) protected them against this inhibition in a concentration dependent manner. Electron microscopy revealed vincristine induced fragmentation and longitudinal disorientation of microtubules in neurites and showed the protection by gangliosides against such damaging effects. Results show that exogenous administration of gangliosides attenuates the neurotoxicity of vincristine in vitro.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
维拉帕米已被证明能够在体外和体内克服P388白血病对长春新碱的获得性耐药。为了研究这种作用的特异性,研究了在加入维拉帕米后对长春新碱细胞毒性的影响,使用的细胞来自8名慢性淋巴细胞白血病患者的外周血淋巴细胞、一个T-急性淋巴细胞性白血病细胞系(GM 3639)的淋巴母细胞,以及8名正常健康志愿者的外周血淋巴细胞。使用差染细胞毒性分析,证明了在1 uM浓度下,维拉帕米能够增强长春新碱对慢性淋巴细胞白血病和GM 3639细胞的体外细胞毒性,浓度为0.04-0.25 ug/L。然而,没有观察到对对照组外周血淋巴细胞的细胞毒性增强。数据表明,维拉帕米优先增强长春新碱对慢性淋巴细胞白血病和GM 3639细胞的体外细胞毒性,但对淋巴细胞没有观察到细胞毒性的增强。
Verapamil has been shown to overcome acquired drug resistance to vincristine in P388 leukemia both in vitro and in vivo. To study the selectivity of this action, the effect of addition of verapamil on the cytotoxicity of vincristine was studied using lymphocytes from eight patients with chronic lymphocytic leukemia, lymphoblasts from a T-acute lymphoblastic leukemia cell line (GM 3639), and peripheral blood lymphocytes from eight normal healthy volunteers. Using the differential staining cytotoxicity assay, it was demonstrated that verapamil at 1 uM concentration potentiated the in vitro cytotoxicity of vincristine on chronic lymphocytic leukemia and GM 3639 cells in concentrations of 0.04-0.25 ug/L. There was however, no enhancement of cytotoxicity noted against the control peripheral blood lymphocytes. The data demonstrate that verapamil preferentially enhances the in vitro cytotoxicity of vincristine on chronic lymphocytic leukemia and GM 3639 cells but no enhancement of cytotoxicity is seen against peripheral blood lymphocytes.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 解毒与急救
保持呼吸道通畅,必要时协助通气。如果出现昏迷、抽搐、低血压和心律失常,则进行治疗。使用甲氧氯普胺治疗恶心和呕吐,使用静脉晶体液治疗胃肠炎引起的液体丢失。对于骨髓抑制,应在经验丰富的血液学家或肿瘤学家的帮助下进行治疗。外渗:立即停止输液,并通过注射器的负压尽可能多地抽回液体。然后给予以下特定治疗:在区域上放置加热垫,间歇加热24小时;抬高肢体。局部注射透明质酸酶可能有益。不要使用冰袋。/对于/去污,如果条件适当,口服活性炭。在小到中等摄入量后,如果可以迅速给予活性炭,则无需进行胃灌洗。由于这些药物的快速细胞内结合,透析和其他体外清除程序通常无效。/抗肿瘤药物/
Maintain an open airway and assist ventilation if necessary. Treat coma, seizures, hypotension, and arrhythmias if they occur. Treat nausea and vomiting with metoclopramide and fluid loss caused by gastroenteritis with intravenous crystalloid fluids. Bone marrow depression should be treated with the assistance of an experienced hematologist or oncologist. Extravasation: Immediately stop the infusion and withdraw as much fluid as possible by negative pressure on the syringe. Then give the following specific treatment: Place a heating pad over the area and apply heat intermittently for 24 hours; elevate the limb. Local injection of hyaluronidase may be beneficial. Do not use ice packs. /For/ decontamination administer activated charcoal orally if conditions are appropriate. Gastric lavage is not necessary after small to moderate ingestions if activated charcoal can be given promptly. Because of the rapid intracellular incorporation of these agents, dialysis and other extracorporeal removal procedures are generally not effective. /Antineoplastic agents/
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
中枢神经系统白血病在接受长春新碱治疗且血液学缓解的患者中的发展被解释为证据,表明长春新碱...穿透血脑屏障的能力较差。长春新碱...可以以比静脉给药大几倍的剂量注入肿瘤的动脉血液供应中,而毒性相当;因此,局部摄取或破坏非常迅速。长春花生物碱似乎主要通过肝脏排泄进入胆汁。
Development of CNS leukemia in patients receiving vincristine and in hematological remission has been interpreted as evidence that ... /vincristine/ penetrates blood-brain barrier poorly. Vincristine ... can be infused into arterial blood supply of tumors in doses several times larger than those that can be admistered iv with comparable toxicity; thus either local uptake or destruction is very rapid. Vinca alkaloids appear to be excreted primarily by liver into bile.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
注射后最初几小时内的尿液排泄在狗和猴子中都很低。在两者中,药物分布到大多数组织中,但浓度最高的发现于肺、肾、脾、胰腺和肝脏。在猴子中,长春新碱及其代谢物迅速从血浆进入脑脊液,形成低浓度的药物,这种状态持续了数天。
Urinary excretion ... over first few hr after injection was ... low in dogs and monkeys. In both ... the drug was distributed to most tissues, but highest concentrations ... found in lung, kidney, spleen, pancreas and liver. In monkeys, vincristine and its metabolites rapidly entered cerebrospinal fluid from plasma to form low concentrations of drug, which persisted for several days.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
硫酸长春新碱从胃肠道的吸收是不可预测的。在肾功能和肝功能正常的患者中,快速静脉注射2毫克剂量的硫酸长春新碱后,血药浓度会立即达到大约0.19-0.89微摩尔/升的峰值,并且药物会迅速从血液中清除。当使用相同剂量的药物时,与快速静脉注射相比,连续静脉输注的血药浓度-时间曲线下面积有所增加。
Vincristine sulfate is unpredictably absorbed from the Gl tract. Following rapid iv injection of a 2 mg dose of vincristine in patients with normal renal and hepatic function, peak serum drug concentrations of approximately 0.19-0.89 uM occur immediately and the drug is rapidly cleared from serum. The area under the serum vincristine concentration time curve has been shown to be increased following continuous iv infusion compared with rapid iv injection of the drug when comparable doses are administered.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
长春新碱及其代谢物(和/或分解产物)在人体组织和液体中的分布尚未被完全表征,但药物在静脉给药后迅速且广泛分布。分布到组织中的药物紧密结合但可逆。长春新碱及其代谢物(和/或分解产物)迅速且广泛地分布到胆汁中,在快速静脉注射药物后2-4小时内胆汁中达到峰值浓度。长春新碱及其代谢物(和/或分解产物)在快速静脉注射后很少穿过血脑屏障,通常不会在脑脊液中以细胞毒浓度出现。
Distribution of vincristine and its metabolites (and/or decomposition products) into human body tissues and fluids has not been fully characterized, but the drug is rapidly and apparently widely distributed following iv administration. Drug that is distributed into tissues is tightly but reversibly bound. Vincristine and its metabolites (and/or decomposition products) are rapidly and extensively distributed into bile, with peak biliary concentrations occurring within 2-4 hr after rapid iv injection of the drug. Vincristine and its metabolites (and/or decomposition products) cross the blood brain barrier poorly following rapid iv injection and generally do not appear in the CSF in cytotoxic concentrations.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 危险等级:
    6.1(a)
  • 危险品运输编号:
    UN 1544
  • 包装等级:
    II
  • 危险类别:
    6.1(a)

SDS

SDS:7e9707be4484f9c048a3f5d296c077a0
查看

制备方法与用途

理化性质

长春新碱(Vincristine, Oncovin, VCR)是从夹竹桃科植物长春花中提取出的生物碱。它具有显著的抗肿瘤作用,目前作为临床抗肿瘤药物使用。在甲醇中重结晶时形成针状结晶,熔点为211~216℃,比旋光度+42°(氯仿)。

长春新碱、长春碱是长春花中具有抗肿瘤活性的二聚吲哚类生物碱,在抗击癌症方面表现出显著疗效。

发现历史

加拿大医生罗伯特·诺布尔(Robert Noble)是一位研究糖尿病的医学家。他的哥哥克拉克·诺布尔(Clark Noble,对发现胰岛素做出了巨大贡献)听说“牙买加人将长春花当作茶来治疗糖尿病”,并将这一消息告知了罗伯特,并寄了一些样品给他。和大多数药物学家一样,罗伯特也是通过民间医学获取信息,然后经过科学验证,分离出有效的化合物以开发新药。

通过给小白鼠和兔子注射长春花提取液,他们发现长春花并不能降低血糖浓度。然而令人惊讶的是,灭菌的长春花提取液却导致了小白鼠肝脏和肾脏脓肿。进一步研究揭示,长春花提取液破坏了小白鼠的免疫系统,并直接损害了脊髓造血细胞,从而降低了血液中负责免疫的能力。

敏锐的罗伯特很快意识到,这种成分可以杀死白细胞。因此,他认为长春花对治疗白血病具有潜在疗效。白血病是由骨髓异常导致不正常白血球大量繁殖所致。

在敏锐地认识到长春花可能对白血病有潜在疗效后,罗伯特邀请了化学家查尔斯·比尔(Charles Beer)加入研究团队,共同着手分离长春花中的特殊成分。1958年,他们最终得到一个具有活性的生物碱,并命名为长春新碱(Vinblastine)。后来与美国著名医药公司Eli Lilly合作研发,成功推出抗癌药物——长春新碱,其疗效比长春花碱更好,是治疗白血病的首选化疗药物,特别对急性淋巴性白血病、霍奇金氏淋巴瘤等癌症有显著效果。

药理作用

长春新碱能抗癌,疗效比长春碱约高10倍。它可用于治疗急性淋巴细胞性白血病,对其他急性白血病、何杰金氏病、淋巴肉瘤、网状细胞肉瘤和乳腺癌也有一定疗效。长春新碱与长春花碱(Vinblastine)、泛洛洛新及泛洛洗汀等一起存在于蔓长春花中的生物碱具有使细胞分裂(有丝分裂)在中期停止的作用,这类似于化疗药物的效果。

适应症
  • 急性白血病,尤其是儿童急性白血病
  • 恶性淋巴瘤
  • 生殖细胞肿瘤
  • 小细胞肺癌、尤文肉瘤、肾母细胞瘤、神经母细胞瘤
  • 乳腺癌、慢性淋巴细胞白血病、消化道癌、黑色素瘤及多发性骨髓瘤等
典型不良反应
  • 骨髓功能抑制
  • 消化道反应
  • 神经系统毒性:四肢麻木、腱反射迟钝或消失、外周神经炎、便秘、麻痹性肠梗阻、运动神经和感受神经及脑神经症状
  • 血栓性静脉炎,注射时漏至血管外可造成局部坏死
化学性质

长春新碱是白色结晶体,易溶于甲醇、乙醇、DMSO等有机溶剂。

用途

天然植物抗肿瘤药,用于治疗急性白血病和恶性淋巴瘤、小细胞肺癌及乳腺癌。

同类化合物

长春西醇 长春西碱 长春花胺 长春花碱 长春罗定 长春素 长春磷汀 长春甘酯 长春瑞宾 长春氮芥 长春氟宁酒石酸盐 长春氟宁 长春曲醇酸 长春曲醇 长春新碱 长春匹定硫酸盐 脱水长春碱 脱乙酰基长春碱酰肼 硫酸长春碱 硫酸长春新碱 硫酸长春地辛 硫酸长春地辛 甲酰基-环氧长春碱 二(N-亚乙基长春地辛)二硫醚 O4-去乙酰基-3',4'-二去氢-4'-脱氧-C'-去甲长春花碱 N-去甲基长春碱 N-(O-4-去乙酰基-长春碱-23-酰基)-L-亮氨酸乙酯 N-(4-叠氮基-3-碘水杨酰)-N'-beta-氨基乙基长春地辛 4-去乙酰基长春花碱 3-(((2-((4-叠氮基-2-硝基苯基)氨基)乙基)氨基)羰基)-O4-去乙酰基-3-去(甲氧羰基)-长春花碱 3''-(beta-氯乙基)-2'',4''-二氧代-3,5''-螺恶唑烷-4-去乙酰氧基长春碱 2,5-哌嗪二酮,1,4-二甲基-3-亚甲基- (3'a,4'a)-4'-脱氧-3',4'-环氧-12'-羟基-长春花碱 12'-iodovinblastine 12'-thiomethylvinblastine 20',20'-difluoro-4'-deoxyvinblastine methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(cyclobutanecarbonylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[[(4-chlorobenzoyl)amino]methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-10-[[(4-methoxybenzoyl)amino]methyl]-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(3,3-dimethylbutanoylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[[(4-nitrobenzoyl)amino]methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[(3-methylbutanoylamino)methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-[[(4-fluorobenzoyl)amino]methyl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(butanoylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[[(3-chlorobenzoyl)amino]methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(cyclopropanecarbonylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[[(2-chlorobenzoyl)amino]methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(2,2-dimethylpropanoylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[(propanoylamino)methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[(pyridine-4-carbonylamino)methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate